SciSparc Finalizes Exclusive Global Out-Licensing Agreement With Polyrizon For SCI-160 Pain Therapy Program Valued At $3M
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. (NASDAQ: SPRC) has finalized an exclusive global out-licensing agreement with Polyrizon Ltd. for its SCI-160 pain therapy program. The deal is valued at $3 million in Polyrizon shares, with potential additional cash payments and fees if development milestones are met.
August 16, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SciSparc Ltd. has entered into an exclusive global out-licensing agreement with Polyrizon Ltd. for its SCI-160 pain therapy program, valued at $3 million in Polyrizon shares. SciSparc may also receive up to $3 million in cash payments if certain development milestones are achieved.
The agreement provides SciSparc with immediate financial consideration in the form of Polyrizon shares and the potential for additional cash payments, which could positively impact its financial position and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100